Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 9;7:12876. doi: 10.1038/s41598-017-13232-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

PARP1 inhibition interferes with recruitment of BER effector XRCC1 and NHEJ mediators XRCC4 & KU70/80 at DNA damage site. (A) Representative image of co-immunofluorescence of XRCC1 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (B) Bar graph displaying number of XRCC1 foci and relative co-localization of XRCC1 foci and γH2A.X foci in indicated treatment group. (C) Representative image of co-immunofluorescence of PARP1 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (D) Representative image of co-immunofluorescence of KU80 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (E) Bar graph displaying relative co-localization of KU80 foci and γH2A.X foci in indicated treatment group. (F) Representative image of co-immunofluorescence of XRCC4 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (G) Bar graph displaying relative co-localization of XRCC4 foci and γH2A.X foci in indicated treatment group.